ImmunoVax
A biotech developing novel cancer vaccines to induce potent and specific anti-tumor immune responses.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $220M
AI Company Overview
A biotech developing novel cancer vaccines to induce potent and specific anti-tumor immune responses.
OncologyImmunology
Technology Platform
A modular antigen delivery platform that combines tumor-specific targets with proprietary adjuvants and vectors to stimulate potent and durable immune activation.
Funding History
1Total raised:$220M
Series A$220M
Opportunities
Potential to become a cornerstone combination therapy in immuno-oncology regimens.
Risk Factors
Clinical efficacy in later-stage trials and the high cost/complexity of personalized approaches are key hurdles.
Competitive Landscape
Faces competition from large pharma and other biotechs in cancer vaccines, but differentiates through its adjuvant technology and focus on defined antigen sets.